Cabotegravir and rilpivirine are administered as injectable preparations. The long-acting injectable combination is administered via intramuscular injection, usually in the buttocks, by a healthcare provider.

The dosing schedule for the injectable formulation of Cabenuva:

Initial dose: The patient is administered two injections of 600 mg of cabotegravir and 900 mg of rilpivirine, once a month for the first two months, which are the loading doses.

Maintenance dose: After the initial doses, the maintenance regimen is the administration of 400 mg of cabotegravir and 600 mg of rilpivirine, once every one or two months, depending on the recommendation of the healthcare provider and the needs of the patient.

Important notes for usage:

• Both drugs are administered through injections, not orally
• The injections must be followed up regularly
• Patients should be observed for any side effects, especially after the first doses.

The injections must be strictly followed as prescribed to achieve maximum effectiveness. Missing doses or irregular injections can reduce the effectiveness of the treatment.

Cabotegravir works by binding to and inhibiting the integrase enzyme, which is part of the insertion process of HIV’s genetic material into the host’s DNA. This step is very important for the replication of the virus. It stops the virus from making copies of itself and spreading throughout the body by blocking this process.

Rilpivirine, as an NNRTI, works by binding to the reverse transcriptase enzyme, thereby blocking its activity. This enzyme is essential for converting HIV’s single-stranded RNA into DNA, which is required for the virus to replicate. By inhibiting reverse transcriptase, rilpivirine reduces the virus’s ability to reproduce and increases the effectiveness of the treatment.

Both drugs work synergistically together in the suppression of HIV replication, the maintenance of undetectable viral load, and the prevention of progression from HIV to AIDS (Acquired Immunodeficiency Syndrome).

As with every medication, Cabenuva – cabotegravir + rilpivirine – is likely to cause side effects. Such side effects include:

Injection site reactions- Pain, redness, inflammation, or swelling at the injected site.

Headache: Some people may experience headaches, especially when starting the treatment.

Fatigue: Feeling tired or weak is common during the initial stages of treatment.

Muscle pain: Some individuals may experience muscle aches or joint pain.

Liver problems: Liver enzyme tests should be regularly checked while taking cabotegravir and rilpivirine because both have been known to affect the liver.

Mood changes: Depression or suicidal ideation has also been experienced by some individuals taking rilpivirine. 

Prolongation of the QT interval: Rilpivirine may increase the QT interval, that is, it can impair the heart’s rhythm when there is already an issue with the heart.

Patients should report any new or unusual symptoms to their healthcare provider immediately.

Hepatic issues: Both cabotegravir and rilpivirine can affect liver function. Liver enzyme levels should be monitored regularly, especially in patients with a history of liver disease or hepatitis.

Drug interactions: Cabotegravir and rilpivirine can interact with other drugs, including some antifungals, antivirals, antibiotics, and antiepileptics. The patient should discuss all medications they are taking, even over-the-counter drugs and supplements, with the healthcare provider.

QT prolongation: Patients with heart conditions, particularly those with a prolonged QT interval, should exercise caution since rilpivirine can exacerbate the condition.

Pregnancy and lactation: This combination of cabotegravir with rilpivirine should be prescribed in pregnant patients only if the benefit outweighs the risk to the fetus. It is not preferred in breastfeeding since both the drugs can cross into breast milk.

Combined Use: Cabotegravir and rilpivirine are both used together as a long-acting combination for HIV treatment. Their co-administration in a single injection form (Cabenuva) is effective for managing HIV when dosed appropriately.

CYP3A4 Interaction: Both drugs are metabolized by CYP3A4, so CYP3A4 inhibitors or inducers can alter their levels. Strong inhibitors may increase concentrations, while inducers may decrease efficacy.

Gastrointestinal Side Effects: Both medications may cause gastrointestinal symptoms, so co-use may increase the likelihood of nausea or diarrhea.

Monitoring: Regular monitoring of HIV viral load is essential when using this combination to ensure efficacy and avoid resistance development.

Loading dose: During the initial two months, administer cabotegravir 600 mg along with rilpivirine 900 mg once every 4 weeks.

Maintenance dosing: Followed by the loading doses, the maintenance dose of cabotegravir is 400 mg and rilpivirine 600 mg to be administered once in every 1 to 2 months depending on patient’s response and recommendation by their healthcare provider.

Cabotegravir and rilpivirine are prescription drugs that should only be prescribed by a healthcare provider knowledgeable about the treatment of HIV. A comprehensive assessment, including the patient’s viral load and general health, should be performed before initiation of therapy. Follow-up visits are also required for injections, side effect monitoring, and assessing the efficacy of the therapy.

1. What is Cabotegravir and Rilpivirine?

   • Cabotegravir and Rilpivirine is a combination medication used for the treatment and maintenance of HIV infection in adults.

2. How does the combination work?

   • Cabotegravir is an integrase strand transfer inhibitor, while Rilpivirine is a non-nucleoside reverse transcriptase inhibitor, and together they prevent the replication of the HIV virus.

3. What is the brand name of the Cabotegravir and Rilpivirine combination?

   • The combination is marketed under the brand name Cabenuva.

4. How is Cabotegravir and Rilpivirine administered?

   • This medication is administered as an intramuscular injection, usually once a month or every two months, after initial oral lead-in therapy.

5. What is the initial treatment regimen before starting Cabotegravir and Rilpivirine injections?

   • Patients typically start with oral Cabotegravir and Rilpivirine for one month before transitioning to the injectable form.

6. Are there any common side effects associated with Cabotegravir and Rilpivirine?

   • Common side effects include injection site reactions, headache, fatigue, and gastrointestinal issues like abdominal pain.

7. Is Cabotegravir and Rilpivirine suitable for all patients?

   • This combination is not suitable for patients with certain contraindications, including those taking specific medications that may interact negatively.

8. What precautions should be taken before using Cabotegravir and Rilpivirine?

   • Patients should undergo testing for HIV-1 resistance before starting treatment to ensure its effectiveness.

9. What is the effectiveness of Cabotegravir and Rilpivirine for HIV treatment?

   • Clinical trials have demonstrated high efficacy, with viral suppression rates comparable to daily oral therapies for HIV.

10. How should Cabotegravir and Rilpivirine be stored?

    • It should be stored in the refrigerator and protected from light. After preparation, it must be used within a specific timeframe as directed by healthcare professionals.

11. Can children use Cabotegravir and Rilpivirine?

    • Cabotegravir and Rilpivirine is currently approved for use in adults and not established in children. Consult a healthcare provider for alternatives suitable for children.

12. Can Cabotegravir and Rilpivirine be used during pregnancy?

    • The safety of Cabotegravir and Rilpivirine during pregnancy has not been fully established. Pregnant individuals should discuss options with their healthcare provider.

13. What should patients do if they miss a dose of Cabotegravir and Rilpivirine?

    • If a dose is missed, patients should contact their healthcare provider for guidance on rescheduling the next injection.

14. Can Cabotegravir and Rilpivirine interact with other medications?

    • Yes, it can interact with certain medications, particularly those affecting liver enzymes. Always inform the healthcare provider about all current medications.

15. What monitoring is required while on Cabotegravir and Rilpivirine?

    • Regular monitoring of viral load, liver function tests, and overall health assessments are necessary to ensure the effectiveness and safety of the treatment.

16. Is there a risk of resistance with Cabotegravir and Rilpivirine?

    • Although resistance is possible, adherence to the prescribed regimen significantly reduces this risk. Regular monitoring for viral load is important.

17. How does the dosing frequency of Cabotegravir and Rilpivirine compare to daily oral HIV medications?

    • The injectable form is administered monthly or bi-monthly, offering a convenient alternative to daily oral medications for those who prefer it.

18. What lifestyle considerations should one take into account while on Cabotegravir and Rilpivirine?

    • Patients are encouraged to maintain a healthy lifestyle, including a balanced diet, regular exercise, and adherence to follow-up appointments.

19. Where can I find more information about Cabotegravir and Rilpivirine?

    • For more information, patients can consult their healthcare provider, visit trusted medical websites, or access HIV support organizations.

20. What is the importance of adherence to the Cabotegravir and Rilpivirine regimen?

    • Adherence is crucial to maintaining effective viral suppression, preventing resistance, and ensuring the overall effectiveness of the treatment regimen.